GIST gastro intestinal stromacel tumor GIST kidney cancer
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients: -patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for >= 8 weeks - Karnofsky score > 70% - age > 18 year. - written informed consent for study;Healthy controls selection: -Healthy individuals: - Karnofsky score > 70% - age > 18 year - written informed consent for study;Patient controls selection Inclusion criteria: -patients with metastastic renal cell cancer or GIST who aren*t treated yet (only interferon alfa or interleukine 2 treatment is allowed when > 12 months ago. - Karnofsky score > 70% - age > 18 year. - written informed consent for study
Exclusion criteria
Exclusion criteria: Patients: - contra-indications for treatment with Sunitinib or Sorafenib - patients who do not speak or write the Dutch language adequately - known brain metastasis - use of psychiatric or anti-epileptic medication - known cognitive disorders unrelated to diagnosis or medication use - radiotherapy on the brain at any time in the past - systemic chemotherapy - in the last 12 months interferon alfa or interleukine-2 treatment - operation in the last 6 months - Diabetes Mellitus - Stroke/TIA;Healthy controls section: - individuals who do not speak or write the Dutch language adequately - use of psychiatric or anti-epileptic medication - known cognitive disorders (Alzheimer e.g.) - radiotherapy on the brain at any time in the past - systemic chemotherapy - operation in the last 6 months - Diabetes Mellitus - stroke/TIA;Patient controls section: - patients who do not speak or write the Dutch language adequately - known brain metastasis - use of psychiatric or anti-epileptic medication - known cognitive disorders unrelated to diagnosis or medication use - radiotherapy on the brain at any time in the past - systemic chemotherapy - in the last 12 months interferon alfa or interleukine-2 treatment - operation in the last 6 months - Diabetes Mellitus - stroke/TIA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| it is a pure describtive study, the results of the neuropsychological tests and the results of the lab tests of the different study groups will be compared | — |
Countries
Netherlands
Outcome results
None listed